News | April 12, 2011

Department of Energy Names Dilon Diagnostics as a Top National Innovator

April 13, 2011 – The U.S. Department of Energy has highlighted Dilon Diagnostics as a success story in the field of medical technology and innovation for commercializing the technologies of the national laboratories. According to the government agency, Dilon and similar entrepreneurs, "build the new industries of the 21st century, and help solve some of our toughest global challenges."

The Dilon 6800 digital gamma camera is based on gamma-imaging technology developed at the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility in Newport News, Va. The imaging technology enables the Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI) procedure and reveals cancerous lesions even at very early stages. BSGI/MBI is a proven technology that can find cancers missed by mammography and ultrasound.

"We are honored to be acknowledged by the Department of Energy as one the country's successful innovators in the medical technology field," said Bob Moussa, president and CEO of Dilon. "We have been able to make a significant impact by utilizing our licensing agreement with Jefferson Lab to help save lives."

More than 250,000 patients have been screened with BSGI/MBI on a worldwide basis.

As a follow-up to mammography, BSGI/MBI helps physicians see the breast more clearly and differentiate benign from malignant tissue. To perform BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as dark spots on the image.

The procedure is especially valuable after a questionable mammogram. This can occur when patients have dense breast tissue; implants; multiple suspicious lesions or clusters of microcalcifications; palpable lesions that can be felt but not detected by mammography or ultrasound; post-surgical or post-therapeutic mass; or if they have been taking hormone replacement therapy.

For more information: www.dilon.com

Related Content

FDA's MQSA Accreditation Bodies Approved for Tomosynthesis Accreditation

Image courtesy of Fujifilm.

Feature | Mammography | May 14, 2018
On April 9, 2018, the U.S. Food and Drug Administration (FDA) announced that all four of its Mammography Quality...
Videos | Breast Imaging | May 08, 2018
ITN Associate Editor Jeff Zagoudis speaks with Karen Hou, M.D., breast radiologist at Northwestern Medicine Central D
Hologic Clarity

Photo courtesy of Hologic.

Feature | Breast Imaging | May 03, 2018 | By Melinda Taschetta-Millane
The global breast imaging market is expected to reach $7.3 billion by 2024, according to a new report by Grand View R
Computer Error Leads to 450,000 Missed U.K. Breast Screening Invites
News | Mammography | May 02, 2018
Since 2009, approximately 450,000 women around age 70 in the United Kingdom did not receive final breast screening...
Pilot Study Initiated for Blood-Based Breast Test
News | Oncology Diagnostics | May 01, 2018
Overlake Medical Center in Bellevue, Wash., announced it has enrolled 85 patients in a pilot study of a blood test to...
360 Photos | Breast Imaging | May 01, 2018
A 360 degree view of an automated breast ultrasound (ABUS) exam room at Northwestern Medicine Central DuPage Hospital
Computers Equal Radiologists in Assessing Breast Density and Associated Breast Cancer Risk
News | Breast Density | May 01, 2018
Automated breast density evaluation was just as accurate in predicting women’s risk of breast cancer, found and not...
Videos | Breast Density | April 26, 2018
ITN Editorial Director Melinda Taschetta-Millane speaks to DenseBreast-info Executive Director JoAnn Pushkin
Overlay Init